resultados del; la fda da un mal reporte a borbec/b - 2007-05-07 21:22:00-04. un informe negativo hecho por reguladores federales provocó que las acciones de la firma miamense dor biopharma cayeran 40% ayer por la tarde. ...
But because of a Blogroll issue with the research, the FDA told Dor BioPharma to show more evidence that orBec works. Hans Klingemann, bone marrow transplant chief at Tufts New England Medical Center. Some encouraging news for those who ...
DOR BioPharma, Inc. today reported the results of its recent End of Review Conference with the Food and Drug Administration for the orBec New Drug Application. The purpose of the meeting was to gain further clarification regarding the ...
